anti-VIPR2 antibody product blog
Tags: Antibody; Polyclonal Antibody; Vasoactive intestinal Polypeptide Receptor 2; anti-VIPR2 antibody; VIPR2;
The VIPR2 vipr2 (Catalog #MBS621410) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Vasoactive intestinal Polypeptide Receptor 2 (VIP Receptor 2, VIP2R, VIPR2, Helodermin Preferring VIP Receptor, Helodermin-preferring VIP Receptor, Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor, PACAP Type III Receptor, VPAC2, VPAC2 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Vasoactive intestinal Polypeptide Receptor 2 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA).Suitable for use in ELISA. Researchers should empirically determine the suitability of the VIPR2 vipr2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VIPR2 vipr2 product has the following accession number(s) (GI #21361557) (NCBI Accession #NP_003373.2) (Uniprot Accession #P41587). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Vasoactive intestinal peptide (VIP) is a 28-aminoacid peptide (human, chr 6q26-q27). Expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a Mol.wt of 20kD. VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder. VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein). VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family. The VIP is 100% conserved in mouse, rat and human. VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease.
Immunogen: Synthetic human VIP-R2 (aa 3-14) (RFHLEIQEEETK). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing VIPR2 are readily searchable from our website. Different antibodies against the same target such as VIPR2 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.